NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sanofi Consumer Healthcare Seeks Approval for Rs 530.1 Cr Material Related Party Transactions
Sanofi Consumer Healthcare India Limited has dispatched a Postal Ballot notice seeking shareholder approval for material related party transactions (RPTs) for CY 2027. The proposed transactions include up to Rs 150.1 crore (Rs 1,501 million) with Opella Healthcare India Private Limited and up to Rs 380 crore (Rs 3,800 million) with Opella SAS. The Rs 380 crore transaction alone represents 43.26% of the company's annual turnover, primarily covering the import of finished goods, central API sourcing, and exports. The e-voting window runs from 7th November 2026 to 6th December 2026, with voting results expected on or before 8th December 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company initiated a postal ballot for shareholder sanction of large RPT contracts scheduled for calendar year 2027.
ஏன் இது முக்கியம்These transactions are vital for core operations, representing over 43% of turnover, ensuring continuous exclusive supply of finished formulations and central API procurement from the parent Opella group.
RPT cap with Opella India: Rs. 1501 MillionRPT cap with Opella SAS: Rs. 3800 MillionOpella SAS RPT as % of turnover: 43.26%E-voting end date: 6th டிசம்பர் 2026
📅 குறுகிய காலம்Neutral operational update; normal voting process expected without market price disruption.
📈 நீண்ட காலம்Secures essential supply chain linkages and product import frameworks from the Opella group for CY 2027.
⚠ அபாய எச்சரிக்கைகள்
High dependence on parent entity Opella SAS for critical finished goods and API procurement without external bidding
👀 கவனிக்க வேண்டியவை
Track the outcome of the postal ballot voting on 8th December 2026 to ensure ordinary resolutions for supply-chain related party contracts are ratified smoothly.
Sanofi Consumer Q3 PAT Rises 22% YoY to ₹76.6 Cr; Revenue Up 12% to ₹263.1 Cr
Sanofi Consumer Healthcare India reported a 12.5% YoY rise in revenue from operations to ₹263.1 crore (₹2,631 million) for the quarter ended September 30, 2026, compared to ₹233.9 crore in Q3 2025. Profit after tax grew 21.8% YoY to ₹76.6 crore (₹766 million) from ₹62.9 crore, driven by 19% domestic sales growth following the full relaunch of previously recalled products. Operating PBT climbed 22.1% YoY to ₹102.7 crore, with quarterly basic EPS expanding to ₹33.26 from ₹27.31. For the nine-month period, revenue rose 16% to ₹728.0 crore while PAT grew 22.8% to ₹213.2 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுSanofi Consumer Healthcare India declared its Q3 2026 financial results showing double-digit growth in top-line and bottom-line.
ஏன் இது முக்கியம்Demonstrates successful market share recovery and commercial traction across core OTC brands post the complete resolution of the 2024–2025 product recalls.
📅 குறுகிய காலம்The strong 22% earnings growth and sustained 19% domestic growth should support sentiment, particularly after the stock's ~30% correction over recent months.
📈 நீண்ட காலம்The business exhibits solid cash-generative characteristics with strong brand moats (Allegra, Combiflam, Avil), though long-term growth hinges on OTC market formalisation and parent Opella strategy.
⚠ அபாய எச்சரிக்கைகள்
Prior history of voluntary product recalls impacting sales continuity
Regulatory sensitivity surrounding OTC medicine classifications in India
👀 கவனிக்க வேண்டியவை
Track sustaining volume growth and operating margins in Q4 2026 now that the low base effect from recalled suspensions (Combiflam, Allegra, Depura Kids) has largely played out.
Sanofi Consumer Q2 Net Profit Up 13% to ₹68.8 Cr; Domestic Sales Grow 12%
Sanofi Consumer Healthcare India (SCHIL) reported a 7% YoY revenue growth to ₹235.7 cr for Q2 2026, driven by a strong 12% increase in domestic sales following product relaunches. Net profit for the quarter rose 13.3% to ₹68.8 cr, while Profit Before Tax (PBT) grew 16% YoY to ₹91.9 cr. The first half of 2026 (H1) shows stronger momentum with revenue up 18% and PBT up 25% YoY. The company maintains a robust liquidity position with cash and bank balances of ₹490.2 cr as of June 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully transitioned into a standalone entity post-demerger, showing consistent double-digit domestic growth and brand recovery.
ஏன் இது முக்கியம்The results validate the 'India for India' strategy and the resilience of core brands like Allegra and Combiflam after historical product recall challenges.
Q2 வருவாய்: ₹2,357 millionQ2 Net Profit: ₹688 millionDomestic Sales Growth (Q2): 12%PBT Margin (Q2): 39%Cash and Bank Balances: ₹4,902 million
📅 குறுகிய காலம்The stock may see positive sentiment as PBT growth (16%) outpaced revenue growth (7%), indicating healthy margin management.
📈 நீண்ட காலம்The structural shift to a specialized consumer healthcare entity allows for better focus on OTC categories; H1 growth of 18% suggests a strong trajectory.
⚠ அபாய எச்சரிக்கைகள்
Export volatility (-9% in Q2)
Regulatory risks regarding OTC drug classifications
Concentration in consumer healthcare segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 12% domestic growth as the 'relaunch' impact normalizes and track the recovery of export sales, which declined 9% this quarter due to a high base.
Sanofi Consumer Healthcare India Limited (SCHIL) has concluded its 3rd Annual General Meeting, with shareholders approving all proposed resolutions. A significant final dividend of Rs 75 per equity share for the financial year ended December 31, 2025, was ratified. While all resolutions passed, the appointment of Price Waterhouse & Co as Statutory Auditors saw notable institutional dissent at 42.72%, though it passed with an overall 91.27% majority. The company remains focused on its 'India for India' strategy following the global Opella group restructuring.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders have formally ratified the FY2025 financial statements, the Rs 75 per share dividend, and the appointment of new Statutory Auditors.
ஏன் இது முக்கியம்This ensures corporate governance continuity and confirms the cash distribution to shareholders, reflecting the company's ability to maintain high payouts despite a slight margin compression in CY2024.
Final Dividend: Rs 75 per shareTotal Shareholders: 49,698Institutional Dissent (Res 4): 42.72%Overall Voting Majority: 91.27%Promoter Votes: 16,414,217
📅 குறுகிய காலம்The stock may see routine price adjustments around the dividend record and payment dates; no major immediate volatility is expected from these results.
📈 நீண்ட காலம்Limited structural impact as the meeting was routine, but the high dividend payout confirms the business remains a strong cash generator for the parent group.
⚠ அபாய எச்சரிக்கைகள்
Significant institutional dissent (42.72%) on the appointment of statutory auditors
👀 கவனிக்க வேண்டியவை
Investors should monitor the dividend credit timeline and watch for the next quarterly results to verify if the 13% expected growth rate is being met through the 'India for India' strategy.
Sanofi Consumer Healthcare India Approves Rs 75 Dividend at 3rd AGM
Sanofi Consumer Healthcare India Limited (SANOFICONR) successfully conducted its 3rd Annual General Meeting on June 26, 2026. A key outcome was the approval of a substantial final dividend of Rs. 75 per equity share for the financial year ended December 31, 2025. The company also confirmed the appointment of Price Waterhouse & Co as statutory auditors and re-appointed Mr. Stanislas Camart as a Director. Management addressed shareholder queries regarding the company's 2025 financial performance and future strategic initiatives.
முக்கிய அம்சங்கள்
Approval of a final dividend of Rs. 75 per equity share of face value Rs. 10 for FY2025Adoption of audited standalone financial statements for the year ended December 31, 2025Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as Statutory AuditorsRe-appointment of Mr. Stanislas Camart as Director following his retirement by rotationManagement provided a strategic overview of business performance and key developments to shareholders
👀 கவனிக்க வேண்டியவை
Investors should track the record date for the Rs. 75 dividend to ensure eligibility for this high-yield payout. The company's ability to maintain such dividends should be monitored alongside its standalone growth performance.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Sanofi Consumer Healthcare India to Hold 3rd AGM; Proposes ₹75 Final Dividend
Sanofi Consumer Healthcare India Limited (SANOFICONR) has scheduled its 3rd Annual General Meeting for June 26, 2026. The Board has recommended a substantial final dividend of ₹75 per equity share for the financial year ended December 31, 2025. The record date for dividend eligibility is June 19, 2026, with the payment scheduled for July 9, 2026. Other key agenda items include the appointment of Price Waterhouse & Co as Statutory Auditors for a five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹75 per equity share of ₹10 each for FY 2025.3rd Annual General Meeting (AGM) scheduled for June 26, 2026, via Video Conferencing.Record date for dividend entitlement is June 19, 2026; payout date is July 9, 2026.Proposed appointment of Price Waterhouse & Co Chartered Accountants LLP as Statutory Auditors for 5 years.Ratification of ₹3,15,000 remuneration for Cost Auditors M/s. Kishore Bhatia & Associates for FY 2026.
👀 கவனிக்க வேண்டியவை
Investors should ensure their bank details and tax residency documents are updated with the RTA by June 19, 2026, to receive the ₹75 dividend. The high dividend payout reflects strong cash flow and shareholder focus.
Sanofi Consumer Healthcare Sets June 19, 2026, as Record Date for Final Dividend
Sanofi Consumer Healthcare India Limited has announced the timeline for its final dividend for the financial year 2025. The company has fixed June 19, 2026, as the record date to determine shareholder eligibility for the payout. The 3rd Annual General Meeting (AGM) is scheduled for June 26, 2026, via video conferencing. The register of members will remain closed from June 20 to June 26, 2026, for the purpose of this dividend distribution.
முக்கிய அம்சங்கள்
Record date for FY 2025 final dividend is fixed as June 19, 2026Book closure period scheduled from June 20, 2026, to June 26, 20263rd Annual General Meeting (AGM) to be held on June 26, 2026, at 3:00 p.m. ISTDividend will be paid to beneficial owners as per NSDL and CDSL records as of June 19, 2026
👀 கவனிக்க வேண்டியவை
Investors seeking the final dividend should ensure they hold shares in their demat accounts before the record date of June 19, 2026. Monitor the upcoming Annual Report for the specific dividend amount per share.
Sanofi Consumer Healthcare Appoints PwC as Statutory Auditor for 5-Year Term
Sanofi Consumer Healthcare India Limited has appointed Price Waterhouse & Co Chartered Accountants LLP (PwC) as its new Statutory Auditor. This appointment fills the casual vacancy created by the resignation of M/s. Kalyaniwalla & Mistry LLP on April 30, 2026. The Board has also recommended PwC for a full five-year term from 2026 to 2031, subject to shareholder approval at the upcoming Annual General Meeting. The transition to a Big Four affiliate firm is typically seen as a positive step for enhancing corporate governance and financial reporting credibility.
முக்கிய அம்சங்கள்
Appointment of PwC to fill casual vacancy effective May 25, 2026, until the next AGM.Recommended 5-year term for PwC starting from the 2026 AGM through to the 2031 AGM.The change follows the resignation of previous auditors M/s. Kalyaniwalla & Mistry LLP on April 30, 2026.PwC India network has over 120 Assurance Partners and 17 branch offices as of April 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the appointment of a globally recognized audit firm as a positive governance move. No immediate action is required other than noting the change for future financial reporting cycles.
Sanofi Consumer Healthcare Statutory Auditor Resigns Due to Audit Fee Dispute
M/s. Kalyaniwalla & Mistry LLP has resigned as the statutory auditor of Sanofi Consumer Healthcare India Limited, effective April 30, 2026. The firm cited the commercial unviability of continuing the audit after the company declined a requested fee increase for FY 2026. The auditors were originally appointed for a five-year term ending in 2028. Notably, the outgoing auditors confirmed there are no other material concerns or issues with obtaining audit evidence.
முக்கிய அம்சங்கள்
Statutory Auditor M/s. Kalyaniwalla & Mistry LLP resigned effective April 30, 2026.The resignation follows the company's refusal to accommodate a fee increase requested on April 25, 2026.The auditor was in the second year of a five-year term originally scheduled to run from 2024 to 2028.Auditor confirmed no concerns regarding financial statements or inability to obtain audit evidence.
👀 கவனிக்க வேண்டியவை
Investors should monitor the appointment of a successor auditor to ensure a smooth transition. While auditor resignations can be a red flag, the explicit mention of a fee dispute suggests this is a commercial disagreement rather than a sign of financial irregularity.
Sanofi Consumer Healthcare Q1 26: Revenue Up 33% to ₹2,292 MN, PAT Rises 36%
Sanofi Consumer Healthcare India (SCHIL) reported a strong Q1 2026 with total revenue reaching ₹2,292 million, a 33% year-on-year increase. Net profit for the quarter grew by 36% to ₹678 million, reflecting disciplined execution and market share gains. Domestic sales were up 15.5%, significantly aided by the relaunch of recalled products, while export sales surged 144% due to a low base effect. This performance marks a positive trajectory for the company following its demerger from Sanofi India in June 2024.
முக்கிய அம்சங்கள்
Total Revenue grew 33% YoY to ₹2,292 million in Q1 2026Net Profit (PAT) increased by 36% YoY to ₹678 millionDomestic sales grew by 15.5%, supported by product relaunches and market share gainsExport sales saw a significant 144% growth, primarily due to a low base in the previous yearKey brands like Allegra, DePURA, Avil, and Combiflam continue to drive the consumer healthcare portfolio
👀 கவனிக்க வேண்டியவை
The strong double-digit growth in both top-line and bottom-line suggests the demerged entity is scaling well; investors should monitor the sustainability of domestic volume growth. The successful relaunch of recalled products is a key positive catalyst for future quarters.
Sanofi Consumer Healthcare Q1 PAT Rises 35.6% YoY to ₹67.8 Cr; Revenue Up 32.8%
Sanofi Consumer Healthcare India reported a strong year-on-year performance for the quarter ended March 31, 2026, with net profit rising 35.6% to ₹678 million. Revenue from operations grew 32.8% YoY to ₹2,292 million, primarily driven by a 15.5% growth in domestic sales following the successful relaunch of key brands like Allegra and Combiflam. While YoY growth is robust, revenue saw a sequential decline of 8.7% compared to the December 2025 quarter. The company maintains healthy margins with Profit Before Tax (PBT) reaching ₹907 million.
முக்கிய அம்சங்கள்
Revenue from operations increased 32.8% YoY to ₹2,292 million from ₹1,726 million.Net Profit (PAT) grew 35.6% YoY to ₹678 million compared to ₹500 million in the year-ago period.Domestic sales grew by 15.5% YoY, aided by the relaunch of Allegra Suspension, Combiflam Suspension, and Depura Kids.Export sales witnessed a significant jump of 144.4% YoY, though on a lower base.Earnings Per Share (EPS) improved to ₹29.44 from ₹21.69 in the same quarter last year.
👀 கவனிக்க வேண்டியவை
Investors should view the strong YoY growth as a sign of successful brand recovery following previous product recalls. The stock remains a watch for steady growth in the consumer healthcare segment, though sequential revenue dips should be monitored for seasonality.
Sanofi Consumer Healthcare Shareholders Approve Key RPTs and MD Remuneration
Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced the successful passage of four key resolutions via postal ballot, all receiving over 99.9% shareholder approval. The resolutions include material related party transactions with Opella Healthcare entities and the establishment of remuneration limits for Non-Executive Directors. Crucially, shareholders approved an amendment to Managing Director Himanshu Bakshi's remuneration to enable his participation in the company's incentive plan. These approvals facilitate operational continuity and align leadership incentives with business performance.
முக்கிய அம்சங்கள்
Material related party transactions with Opella Healthcare India and International SAS approved with over 99.94% votes in favor.Remuneration limits for Non-Executive Directors passed with a near-unanimous 99.99% majority.Amendment to MD Himanshu Bakshi's remuneration for incentive plan participation approved by 99.98% of voters.The voting process involved 50,742 shareholders on record as of March 20, 2026.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong shareholder support for management's compensation structure and operational agreements. The alignment of the Managing Director's pay with incentive plans is a positive governance signal for long-term performance.
Sanofi Consumer Healthcare Reports 21% Revenue Growth and 62.5% ROCE in First Investor Meet
Sanofi Consumer Healthcare India Limited (SCHIL) detailed its strategic transition to a standalone 'Fast Moving Consumer Health' entity following its demerger. For FY2025, the company reported a turnover of approximately ₹880 crore, representing a 21% revenue growth and a 33% increase in PAT. Management is aggressively pivoting from a prescription-only model to a brand-led consumer model, increasing advertising and promotion spends from low single digits to mid-teens. The company maintains a high-quality balance sheet with an operating profit margin of 37% and a robust ROCE of 62.5%.
முக்கிய அம்சங்கள்
Achieved ₹880 crore turnover with a 33% year-on-year increase in Profit After Tax (PAT).Reported a high Return on Capital Employed (ROCE) of 62.5% and operating profit margins of 37%.Increased brand investment (A&P) to mid-teen percentages to drive self-choice consumer growth.Core brands like Avil, Allegra, and Combiflam maintain top 5 positions in their respective categories.Successfully completed product relaunches following precautionary quality recalls, restoring market leadership.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to sustain high margins while scaling marketing spends in the competitive consumer health space. The high ROCE and strong brand legacy make it a premium play in the Indian healthcare sector.
Sanofi Consumer Healthcare Reports 33% PAT Growth and Outlines 2X Reach Strategy
Sanofi Consumer Healthcare India Limited (SCHIL) reported a strong FY2025 with revenue growing 21% to ₹8,784 million and PAT increasing by 33%. The company is pivoting to a Fast Moving Consumer Healthcare (FMCH) model, aiming to double its doctor reach and direct retail coverage. With a high ROCE of 62.5% and market-leading brands like Avil and Allegra, the management is focusing on digital-first demand generation and FMCG-style talent acquisition. The strategy emphasizes scaling consumer engagement to a 60 million multi-media reach to capture high headroom in the Allergy, Pain, and Vitamin D categories.
முக்கிய அம்சங்கள்
Revenue from operations grew 21% YoY to ₹8,784 million with a 36.7% operating profit margin.Profit After Tax (PAT) increased by 33% YoY, supported by a robust 62.5% Return on Capital Employed (ROCE).Company plans to double (2X) its doctor reach and direct retail coverage to improve market access.Maintains strong brand equity with Avil ranked #1 in volume and Allegra ranked #3 in value within their categories.Digital-first approach targeting 30% demand generation and a 60 million multi-media reach.
👀 கவனிக்க வேண்டியவை
Investors should note the company's high capital efficiency (62.5% ROCE) and its aggressive transition toward a retail-heavy FMCH model. The stock remains a strong play on the increasing consumer self-medication trend in India, though execution of the 2X reach target will be the key metric to watch.
Sanofi Consumer Healthcare Seeks Approval for ₹4,614 Million Related Party Transactions
Sanofi Consumer Healthcare India Limited has issued a postal ballot notice seeking shareholder approval for material related party transactions (RPTs) for the 2026 calendar year. The company is proposing a transaction limit of ₹1,200 million with Opella Healthcare India and ₹3,414 million with Opella Healthcare International SAS. Additionally, the ballot covers the approval of remuneration for Non-Executive Directors up to 1% of net profits and an amendment to the Managing Director's incentive plan. The e-voting period runs from March 24, 2026, to April 22, 2026.
முக்கிய அம்சங்கள்
Proposed RPT limit of ₹1,200 million with Opella Healthcare India Private Limited for the year ending December 2026.Proposed RPT limit of ₹3,414 million with Opella Healthcare International SAS for the year ending December 2026.Approval sought for Non-Executive Director commissions not exceeding 1% of annual Net Profits.Amendment to Managing Director Himanshu Bakshi's remuneration terms to enable participation in the company's Incentive Plan.Voting results to be announced on or before April 24, 2026, following the month-long e-voting window.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the vote to ensure that the significant related party transactions are conducted at arm's length and do not adversely affect minority interests. The scale of these transactions reflects the company's operational integration with the global Opella/Sanofi structure.
Sanofi Consumer Healthcare India (SCHIL) reported a robust Q4 performance with revenue growing 47% YoY to ₹2,510 million and net profit surging 50% to ₹665 million. For the full year 2025, the company achieved a 21% revenue growth and a 33% increase in PAT, reaching ₹2,401 million. The board has recommended a substantial dividend of ₹75 per share, reflecting strong cash generation. Growth was primarily driven by a 23% rise in domestic sales and the successful relaunch of recalled products.
முக்கிய அம்சங்கள்
Q4 Revenue grew 47% YoY to ₹2,510 million, while Net Profit rose 50% to ₹665 million.Full-year FY25 PAT increased by 33% to ₹2,401 million on total revenue of ₹8,784 million.Declared a significant dividend of ₹75 per share for the financial year ended December 31, 2025.Domestic sales grew by 23% in Q4, supported by brand relaunches and core portfolio strength.Export sales for Q4 grew 9.3x and full-year exports grew 158%, albeit from a low base.
👀 கவனிக்க வேண்டியவை
The strong double-digit growth and high dividend payout indicate successful post-demerger stabilization and operational efficiency. Investors may consider this a positive signal for long-term value in the consumer healthcare space, given the strength of brands like Combiflam and Allegra.
Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹240 Cr; Recommends ₹75 Dividend
Sanofi Consumer Healthcare India reported a strong financial performance for the year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year surged by 32.6% to ₹2,401 million, driven by robust operational performance and higher other income. The Board has recommended a substantial final dividend of ₹75 per equity share, highlighting strong cash flow generation. Quarterly growth was even more pronounced, with Q4 revenue increasing 47% year-on-year to ₹2,510 million.
முக்கிய அம்சங்கள்
Full-year FY25 revenue increased 21.2% to ₹8,784 million from ₹7,245 million in FY24.Net profit for FY25 rose to ₹2,401 million, up from ₹1,810 million in the previous year.Board recommended a final dividend of ₹75 per equity share (750% of face value).Earnings Per Share (EPS) for FY25 improved significantly to ₹104.27 from ₹78.59.Q4 FY25 net profit stood at ₹665 million, a 50% increase compared to ₹443 million in Q4 FY24.
👀 கவனிக்க வேண்டியவை
Investors should view these results positively given the strong double-digit growth in both top-line and bottom-line, coupled with a high dividend payout. The stock remains attractive for those seeking a combination of growth in the consumer healthcare space and high yield.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
